Areva launches 4 new drugs
Kaitlyn Clay, Staff Writer, [email protected]
“We want to give people one more day to go watch their kids play in a ballgame or just one more day to not worry how they are going to afford the bills for their medicine. Profit is oxygen for our competing companies, but not us. Our oxygen is eliminating worry,” Victor Swaminathan, the president of Areva Pharmaceuticals, said.
The work being done at Areva, located in the Interchange Industrial Complex north of Lanesville since 2014, all boils down to one thing: the people there care about each person they service. Since 2007, when the company was first launched, Areva has been dedicated to the global development, production and distribution of high-quality, affordable pharmaceuticals. The pharmaceuticals created are used for the treatment of cancers, hypertension, heart disease and glaucoma.
The company recently launched four new drugs into the marketplace, which now brings its total to nearly 30 products in the health arena.
For example, one of the new drugs, Capecitabine, can be taken for the treatment of colon, rectal, breast, esophageal, gastric, hepatobiliary, neuroendocrine, pancreatic, ovarian, fallopian tube and peritoneal cancers.
The average process time to get a new drug out to the public usually takes between three and five years. Swaminathan said that time frame used to be much shorter, but, due to the launch of the Affordable Care Act, the FDA had to adjust to new procedures.
“When the ACA was first established, it was the first time in around 70 years that big changes were going to affect the FDA,” he said. “Because all drugs have to be passed through the FDA before hitting the market, this slowed things down quite a bit for pharmacists to launch new drugs. But now, things are getting back to normal after they adjusted to new regulations and we should be seeing a lot more drugs being brought into the market. Now, our drugs can be found in all hospitals and pharmacies in the United States.”
On top of launching four new drugs in the midst of a global pandemic, Areva Pharmaceuticals has also created the ArevaCares Program.
Mark Windley, the company’s vice president of commercial sales, said the program stemmed from one of the company’s main values: caring more about patients than profits.
“The ArevaCares Program comes with a $0 co-pay,” Windley said. “We produce drugs that people will be taking at some of the hardest points in their lives. We don’t want them to have to worry about how they will have extra hundreds of dollars laying around for the co-pay on the drugs needed to literally keep them alive.
“Especially in today’s climate — with the pandemic going on — a lot of things stopped, but not cancer,” he said. “Times are hard for a lot of people, so knowing we can help ease some of that trouble is another way we are trying to help do our part.”
Because of the launch of the new drugs and the release of the ArevaCares Program, both Swaminathan and Windley agreed that the industrial park will soon hum with business. While the current Areva facility is a 60,000-square-foot building with offices and warehouse space, Swaminathan said they have expansion plans in the works as well. He said their hope is to build two more spaces in the park for corporate offices and manufacturing.
“We currently have 18 people on staff and are working on building a sales force in every state,” Swaminathan said. “This place is going to start to pick up steam. We are very proud of the work we have done this far and can’t wait to see the success once we begin to grow.
“We are here for the long haul in this community, and we are excited to contribute to Harrison County,” he said.